First of two supplementary pharmacokinetic studies with RHB-102 for the prevention of radiotherapy- and chemotherapy-induced nausea and vomiting: A drug-food interaction trial.

Trial Profile

First of two supplementary pharmacokinetic studies with RHB-102 for the prevention of radiotherapy- and chemotherapy-induced nausea and vomiting: A drug-food interaction trial.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2015

At a glance

  • Drugs Ondansetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 08 Oct 2013 Positive results demonstrating an extended-release formulation of ondansetron has high bioavailability have been reported in a RedHill Biopharma media release.
    • 08 Oct 2013 Status changed from recruiting to completed based on information reported in a RedHill Biopharma media release.
    • 22 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top